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Introduction
Muckle-Wells syndrome (MWS) is caused by mutations
in the NLRP3-gene encoding cryopyrin, leading to over-
production of IL-1b and other NLRP3 inflammasome
products. Myeloid-derived suppressor cells (MDSCs)
represent a novel innate immune cell subset, are generated
in tumor, infective, and proinflammatory microenviron-
ments and are capable of suppressing T cell responses.
Consequently, MDSCs are considered a key intermediary
in balancing innate and adaptive immune responses, parti-
cularly under chronic disease conditions.
Objectives
We hypothesized that NLRP3 inflammasome-dependent
factors induce the generation of MDSCs in MWS.
Methods
We studied granulocytic MDSC numbers in 25 MWS
patients under anti-IL-1 therapy with canakinumab and
20 healthy controls. After Ficoll density gradient sedi-
mentation, granulocytic MDSCs were characterized as
CD33highCD66bhighIL-4RainterHLA-DRlow neutrophilic
cells in the PBMC fraction, according to previously
established human MDSC analysis methods. The func-
tionality of MACS-isolated MDSCs was assessed using
polyclonal T cell proliferation and cytokine / chemokine
secretion tests. Physician’s global assessment of disease
activity, CRP, ESR, and T helper cell subsets were deter-
mined at the same time points and correlated with
MDSC levels. Serum samples of 22 MWS patients and 5
healthy controls were examined by multiplex technique
for possible MDSC inducing factors.
Results
MWS patients under anti-IL-1 therapy displayed signifi-
cantly elevated MDSC numbers (mean 1.65 ± 0.33 %;
range 0.16 – 5.17 %) compared to healthy controls (mean
0.45 ± 0.05 %; range 0.12 – 1.04%; p = 0.0025), although
clinical MWS-disease activity was generally low at time
of examination. MDSCs were functionally competent, as
they suppressed polyclonal T cell proliferation, Th1, Th2,
and Th17 responses. MDSCs correlated directly with
Treg/Th17 and Treg/Th1 ratios indicating an influence
on T helper cell subsets. Multiplex assays revealed the
established MDSC-inducing growth factors GM-CSF
and VEGF elevated in MWS sera even under anti-IL-1
therapy with canakinumab.
Conclusion
MWS patients under anti-IL-1 therapy display significantly
elevated numbers of granulocytic MDSCs. Increased
MDSCs in MWS might represent a novel autologous anti-
inflammatory mechanism in autoinflammatory conditions
and may serve as a future therapeutic target.
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